The most consequential thing that happened to Humana Inc in the second quarter of 2026 had almost nothing to do with the headline numbers. A federal district court in Fort Worth rejected Humana's challenge to the 2025 Star Ratings in mid-October. The company filed an appeal to the Fifth Circuit in late November that remains pending. Star Ratings are the quality scores Medicare assigns to private Medicare Advantage plans, and they translate directly into the bonus payments the federal government layers on top of base capitation. The court loss means the bonus payments remain compressed in the comparison period. The point of this analysis is that the operating headline is worse than the underlying franchise, and the gap is the trade. Humana Inc shares trade near $394.88. The fifty-two-week range runs from $163.11 to $428.88.
The valuation looks stretched on trailing earnings at roughly thirty-six times, but compresses to under twenty-four times on forward consensus, which is the framing that matters when the Star Ratings drag washes through the comparison base over the next four quarters. The market capitalization sits at roughly $47.4 billion on 120.08 million shares outstanding. Three things make this analyst cautious. First, the Star Ratings lawsuit itself; an adverse appellate ruling would extend the bonus impairment into 2027 and reset expectations again. Second, the MaxHealth acquisition added roughly $908 million of net cash consideration while the parent issued $1.0 billion of junior subordinated notes. Third, the consolidated benefit ratio at ninety-one percent is still a margin headwind and pricing only partially offsets it.
The investment case rests on a single question: does Medicare Advantage scale combined with the CenterWell vertical integration generate enough operating leverage to absorb the Star Ratings cycle and still deliver earnings power that compounds at a multiple the market can underwrite? The second quarter evidence is constructive but not without reservations. Premium revenue grew twenty-six percent in the quarter, membership expanded by more than three million year over year, and CenterWell external services revenue jumped thirty-two percent on the back of the primary care build-out. The transitory pieces, the Star Ratings drag, the value creation initiative charges of $56 million, and the put/call valuation adjustments, are sized and dated. The valuation question is whether a forward multiple in the low twenties fairly discounts the cycle.